Pharmaceuticals

Antiobesity Market 2026–2030: Forecast, Innovation, and Competitive Trends

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the antiobesity market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Antiobesity Market show for the 2026–2030 period?

The antiobesity market size has demonstrated robust growth over recent years. It is anticipated to increase from $4.1 billion in 2025 to $4.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be attributed to several factors including rising global obesity rates, the limited efficacy of lifestyle-only interventions, the availability of appetite suppressants, an escalating metabolic disorder burden, and physician-led weight management strategies.

The antiobesity market is projected for significant expansion over the coming years, with its size expected to reach $6.56 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by factors such as the rising incidence of diabetes and obesity, advancements in hormone-based medications, broader reimbursement coverage, heightened awareness regarding obesity, and the increasing demand for effective and lasting weight loss solutions. Key trends expected during this period include the swift uptake of glp-1 based therapies, a growing inclination towards prescription weight loss medications, the increased application of combination antiobesity treatments, a stronger emphasis on long-term weight management, and improved access to obesity care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3403&type=smp

What Drivers Are Shaping The Development Of The Antiobesity Market?

The increasing incidence of obesity is expected to fuel the expansion of the anti-obesity drugs market in the future. Obesity, a persistent metabolic disorder marked by excessive body fat accumulation, significantly raises the likelihood of severe health issues such as diabetes, cardiovascular diseases, osteoarthritis, and specific malignancies. The growing occurrence of obesity stems from increased intake of highly processed foods rich in sugars, unhealthy fats, and refined carbohydrates, alongside inactive lifestyles that limit physical movement. This escalation in obesity cases highlights a greater demand for potent anti-obesity medical treatments, supportive weight management approaches, and sustained therapeutic options to lessen related health dangers and enhance patient outcomes. For example, as reported by the UK-based World Obesity Federation, a body dedicated to obesity research and advocacy, in March 2024, it is estimated that by 2035, 79% of overweight and obese adults and 88% of overweight and obese children will reside in low and middle income countries. Consequently, the escalating rate of obesity is a key factor driving the growth of the anti-obesity drugs market.

What Segment Types Are Examined In The Antiobesity Market?

The antiobesity market covered in this report is segmented –

1) By Drug Class: Peripherally Acting Anti-Obesity Drugs, Centrally Acting Anti-Obesity Drugs

2) By Type: Prescription Drugs (Rx), OTC Drugs

3) By Medication: Monotherapies, Polytherapies

Subsegments:

1) By Peripherally Acting Anti-Obesity Drugs: Orlistat, Lorcaserin

2) By Centrally Acting Anti-Obesity Drugs: Phentermine, Topiramate, Naltrexone-Bupropion Combination, Liraglutide

What Trends Are Reshaping The Dynamics Of The Antiobesity Market?

Leading companies within the antiobesity market are prioritizing advancements in product development and formulations, specifically involving dual glucose-dependent insulinotropic peptide receptor agonists, aiming to deliver enhanced weight loss, better metabolic results, and increased patient tolerability. Such treatments harness combined effects on suppressing appetite, improving insulin sensitivity, and boosting energy expenditure, thereby achieving greater effectiveness than prior GLP-1-only therapies. As an illustration, in December 2024, the US-based pharmaceutical firm Eli Lilly obtained FDA clearance for Zepbound (tirzepatide), establishing it as the inaugural and sole prescription dual GIP/GLP-1 agonist sanctioned for ongoing weight management. Tirzepatide itself has exhibited substantial efficacy in weight reduction, with individuals in phase 3 trials experiencing considerable decreases in body weight. This new indication for Zepbound is anticipated to solidify Lilly’s dominant position in the field of precision obesity therapy, addressing the increasing need for highly effective, long-duration treatment options.

Who Are The Top-Performing Companies In The Antiobesity Market In Recent Years?

Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Which Region Currently Holds The Largest Share Of The Antiobesity Market?

North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antiobesity Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3403&type=smp

Browse Through More Reports Similar to the Global Antiobesity Market 2026, By The Business Research Company

Antiobesity Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiobesity-global-market-report

Antimony Market Report 2026

https://www.thebusinessresearchcompany.com/report/antimony-global-market-report

Antivenom Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivenom-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795